CUR suppressed cell proliferation and triggered apoptosis by downregulating the protein phosphorylation levels of EGFR, AKT, and ERK; furthermore, the combined use of CUR and gefitinib, an EGFR-targeting inhibitor, synergistically potentiated the inhibitory effect on cell viability, suggesting a role for the EGFR signaling pathway in CUR-induced apoptosis in vemurafenib-resistant melanoma cells [109]. This evidence concerns the gene EGFR and melanoma.